Overview

Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
A Phase 2 Maximal Use Systemic Exposure (MUSE) study evaluating the safety and efficacy of LEO 90100 used once daily in subjects with extensive psoriasis vulgaris.
Phase:
Phase 2
Details
Lead Sponsor:
LEO Pharma